Format

Send to

Choose Destination
Blood. 2015 Jul 23;126(4):445-53. doi: 10.1182/blood-2015-02-585042. Epub 2015 Jun 11.

Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

Author information

1
CHU Clermont-Ferrand, Service d'Hématologie Clinique Adulte et de Thérapie Cellulaire, and Université d'Auvergne, Clermont-Ferrand, France; Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA; Cancer Program, Broad Institute, Cambridge, MA; and Division of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
2
Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA; Cancer Program, Broad Institute, Cambridge, MA; and Division of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Abstract

Defining features of chronic lymphocytic leukemia (CLL) are not only its immunophenotype of CD19(+)CD5(+)CD23(+)sIgdim expressing clonal mature B cells but also its highly variable clinical course. In recent years, advances in massively parallel sequencing technologies have led to rapid progress in our understanding of the CLL genome and epigenome. Overall, these studies have clearly demarcated not only the vast degree of genetic and epigenetic heterogeneity among individuals with CLL but also even within individual patient leukemias. We herein review the rapidly growing series of studies assessing the genetic and epigenetic features of CLL within clinically defined periods of its growth. These studies strongly suggest an evolving spectrum of lesions over time and that these features may have clinical impact.

PMID:
26065654
PMCID:
PMC4513249
DOI:
10.1182/blood-2015-02-585042
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center